X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ETH47 is a first-in-class, broadly protective antiviral candidate which is under phase 1 clinical development for the treatment and prophylaxis of viral asthma exacerbations.
Lead Product(s): ETH47
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETH47
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
MHRA approved company to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47 (induce a mucosal innate immune defense), in healthy participants for the treatment and prophylaxis of respiratory viral infections.
Lead Product(s): ETH47
Therapeutic Area: Infections and Infectious Diseases Product Name: ETH47
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
Under the terms of the agreement, Heqet will lead the development of ETH51, RNA-based therapeutics for heart attack and heart failure, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.
Lead Product(s): ETH51
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ETH51
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Heqet Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.
Lead Product(s): ETH45
Therapeutic Area: Rare Diseases and Disorders Product Name: ETH45
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 29, 2022
Details:
Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 disease.
Lead Product(s): mRNA-based Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: DIOSynVax
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2022
Details:
The proceeds will advance the company’s lead programs ETH47 and ETH42, into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle delivery platforms and increase its manufacturing capabilities.
Lead Product(s): ETH47
Therapeutic Area: Infections and Infectious Diseases Product Name: ETH47
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laureus Capital
Deal Size: $26.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 01, 2022
Details:
Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Lead Product(s): NI007
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Neurimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
